All You Need Is Data: HGS Seizes The Moment To Raise $357M In Public Offering
This article was originally published in The Pink Sheet Daily
Executive Summary
Once facing potential bankruptcy, biotech leverages actual and anticipated good news to double its cash position.
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2009
Thanks to the return of the initial public offering and a strong market for follow-ons, money from public investors made a huge comeback during the third quarter of 2009. The merger and acquisition scorecard totaled $17.3 billion from 22 transactions--four of which topped the billion-dollar mark. And in alliances, most notable was Johnson & Johnson and Elan Corp. PLC's joint venture, which will acquire all of the assets and rights to Elan's Alzheimer's Immunotherapy Program.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2009
Thanks to the return of the initial public offering and a strong market for follow-ons, money from public investors made a huge comeback during the third quarter of 2009. The merger and acquisition scorecard totaled $17.3 billion from 22 transactions--four of which topped the billion-dollar mark. And in alliances, most notable was Johnson & Johnson and Elan Corp. PLC's joint venture, which will acquire all of the assets and rights to Elan's Alzheimer's Immunotherapy Program.
Financings Of The Fortnight: Follow-On Fever
Does the recent rash of follow-on public offerings mean biotech IPOs are around the corner? Recent financings provide reason to think it's possible.